CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer

Shawn F. Johnson, Cristina Cruz, Ann Katrin Greifenberg, Sofia Dust, Daniel G. Stover, David Chi, Benjamin Primack, Shiliang Cao, Andrea J. Bernhardy, Rhiannon Coulson, Jean Bernard Lazaro, Bose Kochupurakkal, Heather Sun, Christine Unitt, Lisa A. Moreau, Kristopher A. Sarosiek, Maurizio Scaltriti, Dejan Juric, José Baselga, Andrea L. RichardsonScott J. Rodig, Alan D. D'Andrea, Judith Balmaña, Neil Johnson, Matthias Geyer, Violeta Serra, Elgene Lim, Geoffrey I. Shapiro

    Research output: Contribution to journalArticleResearchpeer-review

    126 Citations (Scopus)

    Abstract

    © 2016 The Author(s) Although poly(ADP-ribose) polymerase (PARP) inhibitors are active in homologous recombination (HR)-deficient cancers, their utility is limited by acquired resistance after restoration of HR. Here, we report that dinaciclib, an inhibitor of cyclin-dependent kinases (CDKs) 1, 2, 5, and 9, additionally has potent activity against CDK12, a transcriptional regulator of HR. In BRCA-mutated triple-negative breast cancer (TNBC) cells and patient-derived xenografts (PDXs), dinaciclib ablates restored HR and reverses PARP inhibitor resistance. Additionally, we show that de novo resistance to PARP inhibition in BRCA1-mutated cell lines and a PDX derived from a PARP-inhibitor-naive BRCA1 carrier is mediated by residual HR and is reversed by CDK12 inhibition. Finally, dinaciclib augments the degree of response in a PARP-inhibitor-sensitive model, converting tumor growth inhibition to durable regression. These results highlight the significance of HR disruption as a therapeutic strategy and support the broad use of combined CDK12 and PARP inhibition in TNBC.
    Original languageEnglish
    Pages (from-to)2367-2381
    JournalCell Reports
    Volume17
    Issue number9
    DOIs
    Publication statusPublished - 22 Nov 2016

    Keywords

    • BRCA-associated breast cancer
    • CDK inhibitor
    • CDK12
    • dinaciclib
    • homologous recombination repair
    • PARP inhibitor
    • triple-negative breast cancer

    Fingerprint

    Dive into the research topics of 'CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer'. Together they form a unique fingerprint.

    Cite this